In the context of gastrointestinal disorders, misoprostol is specifically indicated for which of the following? (AIIMS May 2012)
|A||Routine management of gastroesophageal reflux disease|
|B||Prophylaxis of ulcers during long term therapy with some NSAIDs|
|C||Eradicating H. pylori in patients with acute duodenal ulcers|
|D||Prevention of acute stress ulcers (e.g. in the postoperative setting)|
a. Misoprostol, a prostaglandin-like agonist, stimulates mucus formation (mucotropic effect), has some weak acid antisecretory activity, stimulates HCO3 secretion, and may protect mucosal cells in other ways (cytoprotective effect).
b. Misoprostol is sometimes used as an adjunct to prevent ulcers in the GI tract caused by NSAIDs when used for chronic condition like rheumatoid arthritis. The NSAIDs can cause mucosal damage by inhibiting prostaglandin synthesis, one consequence of which is reduced formation of mucus that protects the mucosal cells
c. Misoprostol is not used for “routine” management of acid-peptic disorders such as gastric or duodenal ulcers or gastroesophageal reflux disease (GERD).